PRELIMINARY-REPORT OF THE ACTIVITY OF DOCETAXEL IN ADVANCED OR RECURRENT SQUAMOUS-CELL CANCER OF THE CERVIX

Eighteen patients with squamous cell cancer of the cervix were treated with i.v. docetaxel 100 mg/m(2) over 1 h every 21 days. No patient re ceived prior chemotherapy, except as a radiation sensitizer, Median ag e was 42 years (range 30-58) and Zubrod performance status was 1 (0-2) , Ten (59%) patients had prior surgery and 11 (65%) had prior radiatio n therapy, Sixteen patients were evaluable for response, Two patients had a partial response (13%; 95% Cl 0-32%) and eight (50%; 95% Cl 23-7 7%) had stable disease, Dose reduction to 75 mg/m(2) was required in 1 0 patients and to 55 mg/m(2) in one patient, Granulocytopenia was the major hematopoietic toxicity (31% grade 3 and 44% grade 4). Docetaxel is active in patients with squamous cell cancer of the cervix and may be tolerable at this dose schedule.